Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rasheid Smith currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution focus for the portfolio. The alignment of this case to a specific unit suggests a specialized technical review process for the current intellectual property. Practitioners should note that this structure limits the diversity of examiner perspectives currently influencing the portfolio.
The busiest examiner for the company is FAUST, AMBER KATHLEEN, who is responsible for 1 pending office action. Because the total pending actions and the busiest examiner's workload both equal 1, this individual handles the entirety of the current patent examination activity. This concentration requires the applicant to focus their advocacy on a single point of contact, as no other examiners or art units are currently involved. The progress of the intellectual property in this sector is currently subject to the specific requirements of this 1 examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042276 | CATIONIC NANOPARTICLE ADJUVANTS | FAUST, AMBER KATHLEEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042276 | CATIONIC NANOPARTICLE ADJUVANTS | FAUST, AMBER KATHLEEN | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18042276 | CATIONIC NANOPARTICLE ADJUVANTS | FAUST, AMBER KATHLEEN | 1643 | §102§103 | Final Rejection | — | Pending | Feb 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRasheid Smith has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amber Kathleen Faust has the most, with 1 of Rasheid Smith's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
